However, it is noteworthy to underline that CRC cells harboring functional p53 (e.g., HCT-116) fail to trigger apoptosis upon oxaliplatin and TRAIL treatments due to a strong p53-dependent, oxaliplatin-mediated, up-regulation of DcR1 [75]. This evidence concerns the gene TP53 and colorectal carcinoma.